Biocon Company Profile

09:11 EST 12th December 2018 | BioPortfolio

Biocon is India's leading biotechnology enterprise. Over the past 25 years, we have evolved from an enzyme manufacturing company to a fully integrated biopharmaceutical enterprise, focused on healthcare. We apply our proprietary fermentation technologies to develop innovative and effective biomolecules in diabetology, oncology, cardiology and other therapeutic segments. At Biocon, our success has been our ability to develop innovative technologies and products and to rapidly leverage them to adjacent domains. This unique "integrated innovation" approach has yielded a host of patented products and technologies that have enabled multi-level relationships with our global clientele.


1406, Woodbridge Commons
New Jersey
United States of America


Phone: 732 636 2950
Fax: 732 636 2951

News Articles [37 Associated News Articles listed on BioPortfolio]

FDA Approves Mylan and Biocon’s Fulphila, the First Biosimilar to Neulasta

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 4, 2018/PRNewswire/ — Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U....

Mylan, Biocon's Neulasta biosimilar OK'd by FDA

Fulphila, or pegfilgrastim-jmdb, from Mylan and Biocon was approved by the FDA to treat patients with non-myeloid cancer unde -More- 

Biocon grants autoimmune-focused Equillium US and Canadian rights to itolizumab

Biocon Ltd. granted recently founded Equillium Inc. an exclusive license in the US and Canada to develop and sell itolizumab, a monoclonal antibody (MAb) Equillium will name EQ001, and related Biocon ...

Mylan and Biocon’s biosimilar to neulasta gains FDA approval

Mylan and Biocon have secured the US Food and Drug Administration’s (FDA) approval for their fulphila, which is a biosimilar...Read More... The post Mylan and Biocon’s biosimilar to neulasta g...

U.S. FDA Approves Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 4, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and...

Biocon’s biosimilars plant gains clearance from FDA

India-based biologicals specialist Biocon has stated that its biosimilars plant has received a clean bill of health, indicating that it is now compliant with US Food and Drug Administration (FDA) manu...

Biocon consolidated net jumps by 47% in Q1 to Rs. 120 crore

Biocon, a Rs. 4,130 crore leading pharma company, has posted impressive financial performance during the first quarter ended June 2018 and its consolidated net profit moved up by 47 per cent to Rs. 12...

Mylan, Biocon Announce Positive CHMP Opinion For Ogivri, Biosimilar Trastuzumab

CANONSBURG (dpa-AFX) - Mylan N.V. (MYL) and Biocon Ltd. said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has issued a positive opinion recommending ...

Drugs and Medications [0 Results]


PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Biocon's target factory.

Promising effect of rapamycin on multiple sclerosis.

The routine therapies for relapsing-remitting multiple sclerosis (RRMS) are common disease-modifying medications, yet are not effective in all patients. The aim of the present clinical trial was to ev...

Clinical Trials [0 Results]


Companies [6 Associated Companies listed on BioPortfolio]

Biocon Limited

Established in 1978, Biocon Limited is India's largest biotechnology Company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven h...

BioCon Valley® GmbH

Born out of Germany´s "BioRegio" competition in 1996 BioCon Valley represents an interdisciplinary network in the field of modern life sciences and health care.Universities, research and health care ...


Biocon is India's leading biotechnology enterprise. Over the past 25 years, we have evolved from an enzyme manufacturing company to a fully integrated biopharmaceutical enterprise, focused on healthca...


Since 1978 BIOCON has provided highly reliable, custom small animal research services to the region’s leading biomedical scientists. Whether your study involves small animal housing, breeding and co...

Biocon Ltd

More Information about "Biocon" on BioPortfolio

We have published hundreds of Biocon news stories on BioPortfolio along with dozens of Biocon Clinical Trials and PubMed Articles about Biocon for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biocon Companies in our database. You can also find out about relevant Biocon Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Corporate Database Quicklinks

Searches Linking to this Company Record